Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

The efficacy and safety of both approved and investigational drugs for moderate to severe hidradenitis suppurativa offer valuable evidence to guide clinical decision-making in a field where head-to-head trials are largely absent.

When updated food allergy prevention guidelines were directly provided to families, they led to earlier allergen introduction in infants and significantly reduced the prevalence of IgE-mediated peanut, egg, and cow's milk allergies.

Patients with chronic spontaneous urticaria experience inadequate symptom control and significant emotional burdens despite various treatment approaches, highlighting an urgent need for more effective and sustained therapies to improve their quality of life.

The AllergyAware e-learning course effectively trained school personnel on anaphylaxis management, significantly improving their knowledge and confidence in using epinephrine auto-injectors, despite some technical and pacing issues reported by users.

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval

The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.